LW402
/ Shanghai Longwood Biopharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
August 06, 2026
Efficacy and Safety of LW402, A Novel Highly Selective JAK1 Inhibitor, in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized, Double-blind, Placebo-controlled Phase II Trial
(EADV 2026)
- No abstract available
Clinical • P2 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
August 28, 2026
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=480 | Recruiting | Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
May 18, 2026
Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.
(PubMed, Front Pharmacol)
- "LW402's favorable safety profile, predictable PK characteristics, and selective JAK1 inhibition collectively support its continued development for the treatment of autoimmune diseases. http://www.chinadrugtrials.org.cn, identifier CTR20201897."
Clinical • Journal • P1 data • PK/PD data • Cardiovascular • Immunology
April 30, 2026
Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo
(clinicaltrials.gov)
- P2 | N=180 | Not yet recruiting | Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.
New P2 trial • Dermatology • Immunology • Vitiligo
January 28, 2026
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P3 | N=480 | Not yet recruiting | Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.
New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
September 23, 2025
Phase II Study of LW402 in Moderate-to-Severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=144 | Completed | Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 6
Of
6
Go to page
1